MorphoSys AG delivered a ‘wait for the next quarter’ message as its third quarter loss before interest and taxes (EBIT) widened by 79% to €23.5 million despite a 20% increase in revenue. The German antibody developer’s revenue totalled €15 million but a 54% rise in research and development expenses to €34.1 million led to the large increase in the EBIT loss.
